Novo Nordisk and Eli Lilly showcased their competitive strategies in the race for market dominance in the obesity treatment segment during a prominent obesity conference over the weekend. This comes as both companies ramp up efforts to expand access to their GLP-1 medications, which have been gaining visibility in the marketplace.
Novo Nordisk reported that prescriptions for its weight loss medication, Wegovy, have exceeded 3 million since its U.S. release five months ago. CEO Mike Doustdar emphasized this achievement, especially in light of Lilly’s introduction of its own GLP-1 pill, Foundayo, earlier this year. “If that’s not acceleration, then I don’t know what is,” Doustdar remarked, affirming the growth trajectory of Wegovy at the American Diabetes Association’s Scientific Sessions.
In contrast, Lilly CEO Dave Ricks highlighted that Foundayo’s weekly prescription numbers have shown significant growth from the initial 20,000 reported shortly after its April launch. While he did not provide specific figures, Ricks expressed confidence in the pill’s progress and its growing acceptance among providers and patients.
The rivalry between the two pharmaceutical giants was palpable at the convention. Advertising for Wegovy was prominent, while Foundayo promotional material filled other areas of the venue in New Orleans. Both companies are now pivoting their marketing efforts to cater to the senior demographic, particularly with Medicare set to cover GLP-1 drugs for weight loss starting this July. This change will allow seniors to access these medications at a cost-effective rate of $50 per month, a stark contrast to the hundreds they previously paid out of pocket.
Doustdar views the Medicare initiative as a crucial opportunity for Wegovy, arguing that its health benefits—such as reducing cardiovascular risks—should resonate with older adults. “With the Wegovy high dose, why would you not take a product that has the same efficacy as my competitor, but also provides kidney and heart protection?” Doustdar questioned, aiming to position Wegovy as the superior choice for seniors.
On the other hand, Ricks emphasized the convenience of Foundayo as a pivotal selling point. The medication’s flexible consumption—able to be taken with food, water, and other medications—makes it appealing to seniors juggling multiple prescriptions. “Most seniors are on many other medications, and this will just fit right into that without any extra thought,” Ricks stated.
Both companies are also advocating for enhanced insurance coverage for GLP-1 drugs. While analyses have suggested these drugs are cost-effective, insurance providers remain hesitant due to the large pool of potential recipients. Lilly’s data indicates that under 20% of its beneficiaries are currently utilizing the drugs for weight loss, although retention rates are promising. The company is conducting an internal study to evaluate cost outcomes and health impacts associated with GLP-1 use, with results expected later this year.
In their pursuit of innovation, both companies are also working on developing new medications. Lilly recently shared Phase 3 trial data for retatrutide, a novel triple agonist showing promising weight loss results, with nearly half of participants achieving a loss of over 30% of their body weight. Ricks foresees retatrutide primarily benefiting individuals with higher body mass indexes and plans to make it accessible through Lilly’s direct-to-consumer sales platform if it gains FDA approval.
Novo Nordisk’s next potential offering, CagriSema, combines components from Wegovy with a new molecule aimed at enhancing weight loss efficacy. Although its initial performance has raised doubts among investors, Doustdar remains optimistic about its future, anticipating a decision from the FDA by late this year.
Amid these competitive advancements, Doustdar is also focused on revamping Novo Nordisk’s overall approach within the cardiometabolic health sector, reaffirming a commitment to regain market presence and foster sustainable growth. He believes the successful rollout of the Wegovy pill represents a turnaround for the company. “At Novo Nordisk, better days are ahead of them and not just behind,” Doustdar asserted, underlining the necessity of capitalizing on current momentum to establish a lasting impact.
